Business
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-\n-Initial results from safety sentinel cohort expected in 2H 2026-\nCARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib is a potential first-in-class, once-daily oral FGFR3 selective inhibitor that was discovered using the TYRA's in-house SNÅP platform.\n\"Achondroplasia is caused by an alteration in FGFR3, and we believe that precisely targeting the root cause of this condition is the key to transforming care,\" said Todd Harris, CEO of TYRA. \"Dabogratinib is the only oral, FGFR3-selective inhibitor in clinical development for achondroplasia, reflecting our commitment to bring forward therapies that are both innovative and accessible for children and their families. Dosing the first child in BEACH301 is more than a milestone for our company — it's a step toward a future where children with achondroplasia can live healthier, fuller lives.\"\nIt is estimated that 1 in 15,000 to 40,000 children are born with achondroplasia, and approximately 250,000 individuals are affected worldwide. People living with achondroplasia may experience health complications including foramen magnum and spinal stenosis, sleep apnea and disproportionate short stature. An FGFR3 G380R gain of function mutation accounts for approximately 99% of achondroplasia cases.\n\"Dosing the first child in BEACH301 is a pivotal moment for TYRA as we work to bring next-generation, transformational therapies to areas of profound unmet need,\" said Doug Warner, M.D., Chief Medical Officer of TYRA. \"Dabogratinib is designed as an easy-to-take oral option, offering an improved administration approach for children and their families. We are grateful to the achondroplasia community — including healthcare providers, families, caregivers, and advocacy organizations — for partnering with us to shape this program, and we look forward to learning ho...